[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"mirnas\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:mirnas":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":4},"100634528","microgreens-and-mirnas-100634528",false,"NCT07540858","Microgreens and miRNAs","The Effect of Mikrofiliz Application on Serum miRNA Levels Associated With Muscle Damage, Recovery, and the Central Nervous System Following Eccentric Loading","GreenmiRNAs","Inclusion Criteria:Recreationally trained athletes were recruited and randomly allocated to either a microgreen supplementation group or a control group. Inclusion criteria were: (i) being an active athlete, (ii) absence of medical contraindications to exercise (verified by medical clearance), (iii) voluntary participation, and (iv) full adherence to the study protocol.\n\n\\-\n\nExclusion Criteria: Exclusion criteria included: recent musculoskeletal injury (within 6 months), chronic disease or regular medication use, lack of structured training in the previous year, and smoking or alcohol consumption. Participants failing to comply with the protocol, experiencing adverse events, or engaging in high-intensity physical activity during the follow-up period were withdrawn\n\n\\-",true,"MALE","19 Years","24 Years",{"count":22,"type":23},15,"ESTIMATED","INTERVENTIONAL",[26],"NA","In this study, we investigated the impact of a comprehensive microgreen and wheatgrass juice protocol on the miRNA response following a standardized EIMD model and whether microgreen consumption could modulate key miRNA markers of neuromuscular regeneration and metabolic adaptation, thereby offering a novel nutritional approach to enhancing holistic recovery in athletes.",[29,30,31],"Exercise Training","Microgreens","miRNAs","NOT_YET_RECRUITING","2026-04-15",{"date":35,"type":36},"2026-04-20","ACTUAL",{"date":38,"type":23},"2026-05-12",{"date":40,"type":23},"2026-07-30",{"name":42,"class":43},"Çanakkale Onsekiz Mart University","OTHER",{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":17,"sex":52,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":57,"conditions":58,"keywords":62,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":76},"100615786","pten-and-organ-specific-micrornas-in-metastatic-breast-cancer-100615786","NCT07297134","PTEN and Organ-Specific microRNAs in Metastatic Breast Cancer","Serum PTEN Levels and Organ-Specific microRNA Signatures as Predictors of Metastatic Patterns in Breast Cancer: A Prospective Observational Study","PTEN-miR-MBC","Inclusion Criteria:\n\n* Female individuals aged ≥18 years\n* Ability to provide written informed consent\n* Group I (Metastatic BC): Histopathologically confirmed breast cancer and radiologically or clinically proven distant organ metastasis at the time of enrollment\n* Group II (Non-Metastatic BC): Histopathologically confirmed breast cancer with no evidence of distant metastasis\n* Group III (Healthy Controls): Women ≥18 years with no known breast disease and no personal history of malignancy\n\nExclusion Criteria:\n\n* History of any other primary malignancy\n* Known breast disease or breast cancer diagnosis in Group III\n* Immunosuppressive therapy that may alter immune or biomarker profiles\n* Active infection or inflammatory condition that may alter biomarker levels\n* Inability or unwillingness to provide informed consent\n* Severe hepatic, renal, or hematologic dysfunction\n* Current pregnancy or lactation","FEMALE","18 Years",{"count":55,"type":23},160,"OBSERVATIONAL","This prospective observational study aims to evaluate serum levels of PTEN, a tumor suppressor gene, and organ-specific microRNAs (miRNAs) associated with metastatic patterns in breast cancer. Serum samples will be analyzed using quantitative reverse transcription polymerase chain reaction (qRT-PCR)-based miRNA profiling and enzyme-linked immunosorbent assay (ELISA)-based PTEN quantification. Three groups will be included: patients with metastatic breast cancer (n=80), patients with non-metastatic early-stage breast cancer (n=40), and healthy controls (n=40).\n\nThe primary objective is to identify serum biomarkers that differentiate metastatic from non-metastatic disease. Secondary analyses will evaluate correlations between biomarker levels and organ-specific metastatic involvement, including bone, lung, liver, and brain metastases. Findings from this study may support the development of a noninvasive serum-based tool for predicting metastatic patterns in breast cancer.",[59,60,31,61],"Breast Cancer","Metastatic Breast Cancer","PTEN",[59,60,31,61,63,64,65],"Breast Cancer Biomarkers","Organ Specific Metastasis","miRNA Profiling","RECRUITING","2026-01-26",{"date":69,"type":36},"2026-01-27",{"date":71,"type":36},"2025-12-01",{"date":73,"type":23},"2026-12",{"name":75,"class":43},"Atlas University",1]